person · Reporting owner
te Boekhorst Paul Francis Olivier
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IMMUCELL CORP /DE/ICCC · Entity 6837 | Director · President and CEO | June 18, 2026 | June 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IMMUCELL CORP /DE/
Report date June 18, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $.01 per shareSEC Table I · non-derivative | Direct | 17,785 |
Reported balance
After 2026-06-18 transaction · row 1
1 source rowRow 1 · 2026-06-18 · Purchase · Acquired 8,000 · Balance 17,785 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 18, 2026 Filed Jun 22, 2026 12:33 UTC | IMMUCELL CORP /DE/ ICCC · Entity 6837 | PurchaseCommon Stock, par value $.01 per share | 8,000 | $9.50 | $75,960.00 |
DisclosureSEC source: 0001437749-26-021258 · rdgdoc.xml · nonDerivative · entry 1 te Boekhorst Paul Francis Olivier · CIK 0002095704 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,785 Read SEC document |
| January 27, 2026 Filed Jan 29, 2026 16:40 UTC | IMMUCELL CORP /DE/ ICCC · Entity 6837 | GrantStock Options (right to buy) · Derivative | 110,000 | $0.00 Strike: $6.27 | $0.00 |
DisclosureSEC source: 0001437749-26-002366 · rdgdoc.xml · derivative · entry 1 te Boekhorst Paul Francis Olivier · CIK 0002095704 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2036-01-27 F1 · derivative.exercise_date: Option grant made to Mr. te Boekhorst in connection with his employment as President and CEO. The option shall be treated as an incentive stock option to the maximum extent permitted by the Internal Revenue Code of 1986, as amended, with the balance treated as nonqualified stock option. One hundred percent of the stock option will vest when the Issuer's net operating income for four consecutive calendar quarters equals or exceeds 300% of the Issuer's audited net operating income for its 2025 fiscal year. Read SEC document |
| January 27, 2026 Filed Mar 23, 2026 13:47 UTC Amendment | IMMUCELL CORP /DE/ ICCC · Entity 6837 | GrantStock Options (right to buy) · Derivative | 109,500 | $0.00 Strike: $6.27 | $0.00 |
DisclosureSEC source: 0001437749-26-009312 · rdgdoc.xml · derivative · entry 1 te Boekhorst Paul Francis Olivier · CIK 0002095704 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,500 Underlying: Common Stock · 109,500 shares Expires 2036-01-27 F1 · shares: This amendment amends the previously reported transaction effective on 1/27/2026 to disclose the correct number of shares included in the option award. F2 · derivative.exercise_date: Option grant made to Mr. te Boekhorst in connection with his employment as President and CEO. The option shall be treated as an incentive stock option to the maximum extent permitted by the Internal Revenue Code of 1986, as amended, with the balance treated as nonqualified stock option. One hundred percent of the stock option will vest when the Issuer's net operating income for four consecutive calendar quarters equals or exceeds 300% of the Issuer's audited net operating income for its 2025 fiscal year. Read SEC document |
| December 04, 2025 Filed Dec 4, 2025 21:11 UTC Amendment | IMMUCELL CORP /DE/ ICCC · Entity 6837 | PurchaseCommon Stock $0.10 par value per share | 2,432 | $5.50 | $13,376.49 |
DisclosureSEC source: 0001437749-25-036913 · rdgdoc.xml · nonDerivative · entry 2 te Boekhorst Paul Francis Olivier · CIK 0002095704 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,738 F2 · shares: This amendment amends the previously reported transaction effective on 12/3 to disclose the correct amount and price of shares purchased, and the correct transaction date. Read SEC document |
| December 03, 2025 Filed Dec 3, 2025 21:14 UTC | IMMUCELL CORP /DE/ ICCC · Entity 6837 | PurchaseCommon Stock $0.10 par value per share | 3,521 | $5.04 | $17,747.95 |
DisclosureSEC source: 0001437749-25-036794 · rdgdoc.xml · nonDerivative · entry 3 te Boekhorst Paul Francis Olivier · CIK 0002095704 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,785 Read SEC document |
| December 03, 2025 Filed Dec 3, 2025 21:14 UTC | IMMUCELL CORP /DE/ ICCC · Entity 6837 | PurchaseCommon Stock $0.10 par value per share | 2,556 | $5.00 | $12,787.67 |
DisclosureSEC source: 0001437749-25-036794 · rdgdoc.xml · nonDerivative · entry 2 te Boekhorst Paul Francis Olivier · CIK 0002095704 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,264 Read SEC document |
| December 03, 2025 Filed Dec 4, 2025 21:11 UTC Amendment | IMMUCELL CORP /DE/ ICCC · Entity 6837 | PurchaseCommon Stock $0.10 par value per share | 3,598 | $5.05 | $18,151.91 |
DisclosureSEC source: 0001437749-25-036913 · rdgdoc.xml · nonDerivative · entry 1 te Boekhorst Paul Francis Olivier · CIK 0002095704 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,306 F1 · shares: This amendment amends the previously reported transaction effective on 12/3 to disclose the correct amount and price of shares purchased. Read SEC document |
| December 02, 2025 Filed Dec 3, 2025 21:14 UTC | IMMUCELL CORP /DE/ ICCC · Entity 6837 | PurchaseCommon Stock $0.10 par value per share | 3,708 | $4.87 | $18,052.77 |
DisclosureSEC source: 0001437749-25-036794 · rdgdoc.xml · nonDerivative · entry 1 te Boekhorst Paul Francis Olivier · CIK 0002095704 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,708 Read SEC document |
| November 07, 2025 Filed Nov 12, 2025 13:43 UTC | IMMUCELL CORP /DE/ ICCC · Entity 6837 | GrantStock Options (right to buy) · Derivative | 74,277 | $6.10 Strike: $6.10 | $453,089.70 |
DisclosureSEC source: 0001437749-25-034257 · rdgdoc.xml · derivative · entry 1 te Boekhorst Paul Francis Olivier · CIK 0002095704 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,260 Underlying: Common Stock · 74,277 shares Expires 2035-11-07 F1 · derivative.exercise_date: Option grant made to Mr. te Boekhorst in connection with his commencement of employment as President and CEO. The option shall be treated as an incentive stock option to the maximum extent permitted by the Internal Revenue Code of 1986, as amended, with the balance treated as a nonqualified stock option. The stock option vests as follows: 24,759 options on the first, second, and third anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.